Physician profile
Michelle Gray
NPI 1336735240
$1,584.95
in general payments reported to CMS, 2019-2025
18 companies · $50.34 in 2025
The $50.34 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $615 · 2023: $461 · 2024: $458 · 2025: $50.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $969.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $405.32 | 2022-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $250.75 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $241.24 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $177.40 | 2022 | |
| Amgen INC. | $128.09 | 2023-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $64.98 | 2023-2024 | |
| Acella Pharmaceuticals, LLC | $59.56 | 2023-2024 | NP Thyroid 60 |
| Idorsia Pharmaceuticals US INC | $36.57 | 2023 | Quviviq |
| Exact Sciences Corporation | $33.61 | 2025 | The Cologuard Plus Collection Kit |
| Hologic Sales and Service, LLC | $32.42 | 2022 | |
| Ibsa Pharma INC. | $29.62 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.73 | 2023-2024 | Xifaxan |
| Philips North America LLC | $22.13 | 2024 | (Ck7) Extended Holter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.58 | 2023 | Ofev |
| Alk-Abello, INC | $15.84 | 2024 | Ragwitek, Odactra, Grastek |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $15.00 | 2024 | Xyosted |
| Nabriva Therapeutics, Plc | $14.83 | 2022 | |
| Shield Therapeutics INC | $13.28 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.